STOCK TITAN

[Form 4] AnaptysBio, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Hollings Renton of AnaptysBio reported a sale of 3,015 shares of common stock at $23.97 per share on June 18, 2025. Following the transaction, Renton retains direct ownership of 4,965 shares.

Key details of the transaction:

  • The sale was executed under a Rule 10b5-1 trading plan established on March 14, 2024
  • The shares were sold to cover tax obligations related to the vesting of restricted stock units on June 15, 2025
  • Total transaction value: approximately $72,269

This insider transaction represents a routine sale for tax purposes rather than a discretionary trading decision, as it was pre-planned through a 10b5-1 trading plan and specifically tied to RSU vesting obligations.

Il direttore Hollings Renton di AnaptysBio ha comunicato la vendita di 3.015 azioni ordinarie a 23,97 $ per azione il 18 giugno 2025. Dopo questa operazione, Renton detiene direttamente 4.965 azioni.

Dettagli principali della transazione:

  • La vendita è stata effettuata nell'ambito di un piano di trading Rule 10b5-1 istituito il 14 marzo 2024
  • Le azioni sono state vendute per coprire obblighi fiscali legati al vesting di unità azionarie vincolate (RSU) del 15 giugno 2025
  • Valore totale della transazione: circa 72.269 $

Questa operazione interna rappresenta una vendita di routine per motivi fiscali e non una decisione di trading discrezionale, essendo stata pianificata in anticipo tramite un piano di trading 10b5-1 e strettamente collegata agli obblighi di vesting delle RSU.

El director Hollings Renton de AnaptysBio informó la venta de 3.015 acciones ordinarias a 23,97 $ por acción el 18 de junio de 2025. Tras la operación, Renton mantiene la propiedad directa de 4.965 acciones.

Detalles clave de la transacción:

  • La venta se realizó bajo un plan de negociación Rule 10b5-1 establecido el 14 de marzo de 2024
  • Las acciones fueron vendidas para cubrir obligaciones fiscales relacionadas con la consolidación de unidades de acciones restringidas (RSU) el 15 de junio de 2025
  • Valor total de la transacción: aproximadamente 72.269 $

Esta transacción interna representa una venta rutinaria por motivos fiscales y no una decisión discrecional de trading, ya que fue preestablecida mediante un plan de negociación 10b5-1 y está específicamente vinculada a obligaciones de consolidación de RSU.

AnaptysBio의 이사 Hollings Renton은 2025년 6월 18일에 보통주 3,015주를 주당 23.97달러에 매도했다고 보고했습니다. 거래 후 Renton은 직접적으로 4,965주를 보유하고 있습니다.

거래 주요 내용:

  • 매도는 2024년 3월 14일에 설정된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다
  • 주식은 2025년 6월 15일 제한 주식 단위(RSU) 취득에 따른 세금 의무를 충당하기 위해 매도되었습니다
  • 총 거래 금액: 약 72,269달러

이번 내부자 거래는 10b5-1 거래 계획을 통해 사전에 계획된 세금 목적의 일상적인 매도이며, 임의적인 거래 결정이 아니라 RSU 취득 의무와 직접 관련된 것입니다.

Le directeur Hollings Renton de AnaptysBio a déclaré la vente de 3 015 actions ordinaires à 23,97 $ par action le 18 juin 2025. Suite à cette transaction, Renton conserve la propriété directe de 4 965 actions.

Détails clés de la transaction :

  • La vente a été réalisée dans le cadre d’un plan de trading Rule 10b5-1 établi le 14 mars 2024
  • Les actions ont été vendues pour couvrir des obligations fiscales liées à l’acquisition de Restricted Stock Units (RSU) le 15 juin 2025
  • Valeur totale de la transaction : environ 72 269 $

Cette transaction d’initié représente une vente de routine à des fins fiscales plutôt qu’une décision de trading discrétionnaire, puisqu’elle a été planifiée à l’avance via un plan de trading 10b5-1 et est spécifiquement liée aux obligations d’acquisition des RSU.

Direktor Hollings Renton von AnaptysBio meldete am 18. Juni 2025 den Verkauf von 3.015 Stammaktien zu je 23,97 $. Nach der Transaktion hält Renton direkt 4.965 Aktien.

Wichtige Details der Transaktion:

  • Der Verkauf erfolgte im Rahmen eines am 14. März 2024 eingerichteten Rule 10b5-1 Handelsplans
  • Die Aktien wurden verkauft, um Steuerverpflichtungen im Zusammenhang mit der Ausübung von Restricted Stock Units (RSU) am 15. Juni 2025 zu decken
  • Gesamtwert der Transaktion: ca. 72.269 $

Diese Insider-Transaktion stellt einen routinemäßigen Verkauf aus steuerlichen Gründen dar und ist keine diskretionäre Handelsentscheidung, da sie vorab durch einen 10b5-1 Handelsplan geplant wurde und speziell an die RSU-Vesting-Verpflichtungen gebunden ist.

Positive
  • None.
Negative
  • None.

Il direttore Hollings Renton di AnaptysBio ha comunicato la vendita di 3.015 azioni ordinarie a 23,97 $ per azione il 18 giugno 2025. Dopo questa operazione, Renton detiene direttamente 4.965 azioni.

Dettagli principali della transazione:

  • La vendita è stata effettuata nell'ambito di un piano di trading Rule 10b5-1 istituito il 14 marzo 2024
  • Le azioni sono state vendute per coprire obblighi fiscali legati al vesting di unità azionarie vincolate (RSU) del 15 giugno 2025
  • Valore totale della transazione: circa 72.269 $

Questa operazione interna rappresenta una vendita di routine per motivi fiscali e non una decisione di trading discrezionale, essendo stata pianificata in anticipo tramite un piano di trading 10b5-1 e strettamente collegata agli obblighi di vesting delle RSU.

El director Hollings Renton de AnaptysBio informó la venta de 3.015 acciones ordinarias a 23,97 $ por acción el 18 de junio de 2025. Tras la operación, Renton mantiene la propiedad directa de 4.965 acciones.

Detalles clave de la transacción:

  • La venta se realizó bajo un plan de negociación Rule 10b5-1 establecido el 14 de marzo de 2024
  • Las acciones fueron vendidas para cubrir obligaciones fiscales relacionadas con la consolidación de unidades de acciones restringidas (RSU) el 15 de junio de 2025
  • Valor total de la transacción: aproximadamente 72.269 $

Esta transacción interna representa una venta rutinaria por motivos fiscales y no una decisión discrecional de trading, ya que fue preestablecida mediante un plan de negociación 10b5-1 y está específicamente vinculada a obligaciones de consolidación de RSU.

AnaptysBio의 이사 Hollings Renton은 2025년 6월 18일에 보통주 3,015주를 주당 23.97달러에 매도했다고 보고했습니다. 거래 후 Renton은 직접적으로 4,965주를 보유하고 있습니다.

거래 주요 내용:

  • 매도는 2024년 3월 14일에 설정된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다
  • 주식은 2025년 6월 15일 제한 주식 단위(RSU) 취득에 따른 세금 의무를 충당하기 위해 매도되었습니다
  • 총 거래 금액: 약 72,269달러

이번 내부자 거래는 10b5-1 거래 계획을 통해 사전에 계획된 세금 목적의 일상적인 매도이며, 임의적인 거래 결정이 아니라 RSU 취득 의무와 직접 관련된 것입니다.

Le directeur Hollings Renton de AnaptysBio a déclaré la vente de 3 015 actions ordinaires à 23,97 $ par action le 18 juin 2025. Suite à cette transaction, Renton conserve la propriété directe de 4 965 actions.

Détails clés de la transaction :

  • La vente a été réalisée dans le cadre d’un plan de trading Rule 10b5-1 établi le 14 mars 2024
  • Les actions ont été vendues pour couvrir des obligations fiscales liées à l’acquisition de Restricted Stock Units (RSU) le 15 juin 2025
  • Valeur totale de la transaction : environ 72 269 $

Cette transaction d’initié représente une vente de routine à des fins fiscales plutôt qu’une décision de trading discrétionnaire, puisqu’elle a été planifiée à l’avance via un plan de trading 10b5-1 et est spécifiquement liée aux obligations d’acquisition des RSU.

Direktor Hollings Renton von AnaptysBio meldete am 18. Juni 2025 den Verkauf von 3.015 Stammaktien zu je 23,97 $. Nach der Transaktion hält Renton direkt 4.965 Aktien.

Wichtige Details der Transaktion:

  • Der Verkauf erfolgte im Rahmen eines am 14. März 2024 eingerichteten Rule 10b5-1 Handelsplans
  • Die Aktien wurden verkauft, um Steuerverpflichtungen im Zusammenhang mit der Ausübung von Restricted Stock Units (RSU) am 15. Juni 2025 zu decken
  • Gesamtwert der Transaktion: ca. 72.269 $

Diese Insider-Transaktion stellt einen routinemäßigen Verkauf aus steuerlichen Gründen dar und ist keine diskretionäre Handelsentscheidung, da sie vorab durch einen 10b5-1 Handelsplan geplant wurde und speziell an die RSU-Vesting-Verpflichtungen gebunden ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RENTON HOLLINGS

(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 S(1) 3,015(2) D $23.97 4,965 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024.
2. Shares sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units on June 15, 2025.
/s/ Eric Loumeau, Attorney-in-Fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ANAB shares did Director Hollings Renton sell on June 18, 2025?

Director Hollings Renton sold 3,015 shares of ANAB common stock on June 18, 2025 at a price of $23.97 per share.

What was the purpose of ANAB Director Renton's stock sale in June 2025?

The shares were sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units that occurred on June 15, 2025.

How many ANAB shares does Director Renton own after the June 2025 transaction?

Following the reported transaction, Director Hollings Renton directly owns 4,965 shares of ANAB common stock.

Was ANAB Director Renton's stock sale part of a pre-planned trading arrangement?

Yes, the sale was executed pursuant to a Rule 10b5-1 trading plan that Director Renton adopted on March 14, 2024.
Anaptysbio Inc

NASDAQ:ANAB

ANAB Rankings

ANAB Latest News

ANAB Latest SEC Filings

ANAB Stock Data

670.46M
27.86M
4.41%
121.92%
29.45%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO